Compare Boston Beer Company Inc (SAM) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Beer Company Inc vs Twist Bioscience Corp — how do they compare? Boston Beer Company Inc trades at $174.88 (market cap $1.73B), while Twist Bioscience Corp trades at $158.01 (market cap $10.32B). The key difference: Twist Bioscience Corp is far larger — about 6× Boston Beer Company Inc's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Boston Beer Company Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Boston Beer Company Inc for 59 Days and Twist Bioscience Corp for 27 Days on average.
| SAM | TWST | |
|---|---|---|
Market Cap | $1.73B | $10.32B |
Volume | 196,621 | 5,894,998 |
Sector | Consumer Staples | Health |
52-Week High | $260.05 | $205.00 |
52-Week Low | $161.08 | $25.45 |
Typical Hold Time | 59 Days | 27 Days |
Enterprise Value | $1.50B | $10.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Beer Company (SAM) trades at $168.16, down 1.3% with a neutral technical outlook. The stock shows mixed fundamentals with a P/E of 22.66 and P/S of 0.92, but negative net income margin of -3.64% and ROE of -8.61%. Recent earnings missed expectations in Q1 and Q2 2026, though Q4 2025 beat estimates. The company maintains positive operating cash flow of $270M in 2025 while expanding brand innovation with new product launches and marketing initiatives.
SAM faces headwinds from volume declines and cost pressures, but brand investments and new product categories offer growth potential. Analyst consensus is cautious with 72% hold ratings, though the $204.44 price target suggests 22% upside. Key risks include competitive pressures and shifting consumer preferences in the alcoholic beverage market.
TWST trades at $152.05, down 8.94% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $376.57 million in 2025, but profitability remains elusive with a net income margin of -31.66%. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, providing a potential growth catalyst amid ongoing losses.
The outlook is mixed; analyst consensus is bullish with a $145.20 price target, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on the company's ability to monetize its AI collaborations and achieve profitability, while downside risks include cash burn and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
